Browsing Category
Pharma Industry News
4718 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Novartis strengthens oral BTK franchise as Rhapsido expands beyond chronic spontaneous urticaria
Novartis expands Rhapsido into symptomatic dermographism as early sales grow and remibrutinib advances across MS and immune diseases.
Cerevance advances non-dopaminergic Parkinson’s strategy after positive solengepras Phase 3 trial
Cerevance’s solengepras wins Phase 3 in Parkinson’s disease, opening an FDA path and a potential first-in-class GPR6 commercial opportunity.
Why Sun Pharma may move part of its $12bn Organon funding into rupee debt
Sun Pharmaceutical Industries will ask its board on October 12 to consider up to â‚ą15,000 crore of listed unsecured NCDs, opening a potentially important refinancing route as it prepares for the $11.75 billion Organon acquisition.
ArriVent shares plunge as FURVENT miss shifts attention to PACC lung cancer and ADC pipeline
ArriVent shares plunge after firmonertinib misses the FURVENT Phase 3 endpoint, putting its first-line exon 20 lung cancer strategy at risk.
Ribo enters obesity RNAi race as RBD3133 moves toward first human study in Europe
Suzhou Ribo Life Science has filed for a European Phase I trial of RBD3133, taking its first obesity candidate toward human testing as multiple RNAi developers pursue INHBE as a potential fat-selective alternative or complement to incretin therapies.
Avacta’s (AIM: AVCT) AVA6103 human data: What is proven before the 2027 efficacy test?
Avacta has reported preliminary controlled-release evidence from 19 patients treated with AVA6103, but tumour-selective delivery and clinical efficacy remain unconfirmed. Its latest ÂŁ12.5 million financing places additional attention on the anticipated 2027 results.
Click Therapeutics faces reimbursement test as Motivista opens new schizophrenia treatment market
Motivista wins FDA clearance for schizophrenia negative symptoms as Click Therapeutics turns to payer coverage, adoption and commercial launch.
BridgeBio’s next rare-disease franchise approaches FDA decision with new BBP-418 cardiac evidence
BridgeBio’s BBP-418 adds encouraging cardiac data ahead of a November FDA decision that could create the first approved LGMD therapy.
Asieris puts Cevira Europe launch in Theramex hands as deal tops $250m
Asieris has handed Theramex exclusive Cevira rights across Europe, Australia, New Zealand and Turkey in a deal worth more than $250 million if milestones are achieved, turning a China-approved cervical precancer therapy into a broader international commercialisation test.
CSL commits US$355m to lixudebart as rare kidney pipeline gains strategic weight
CSL is committing US$355 million upfront and funding a multi-indication clinical programme around Alentis Therapeutics’ lixudebart, giving the Australian biopharma group a potential new nephrology anchor as its existing Vifor portfolio faces material revenue headwinds.